Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients

详细信息    查看全文

• 作者：Andrea Sartore-Bianchi^a ; Filippo Pietrantonio^b ; Alessio Amatu^a ; Massimo Milione^c ; Andrea Cassingena^a ; Silvia Ghezzi^a ; Marta Caporale^b ; Rosa Berenato^b ; Chiara Falcomatà ; ^d ; ^e ; Alessio Pellegrinelli^c ; Alberto Bardelli^d ; ^e ; Michele Nichelatti^a ; Federica Tosi^a ; Filippo De Braud^b ; Federica Di Nicolantonio^d ; ^e ; Ludovic Barault^d ; ^e ; ¹ ; ^{ludovic.barault@unito.it} ; Salvatore Siena^a ; ^f ; ¹
• 关键词：MGMT ; Immunohistochemistry ; DNA methylation ; Digital PCR ; Metastatic colorectal cancer ; Alkylating agent
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：71
• 期：Complete
• 页码：43-50
• 全文大小：1172 K
• 卷排序：71

文摘

Alkylating agent treatment is efficient in a limited subpopulation of metastatic colorectal cancer (mCRC) patient. Improved patient selection is warranted. Dual assessment of O(6)-methylguanine-DNA-methyltransferase (immunohistochemistry + digital PCR for methylation) is proposed. Retrospectively, combined score enhanced selection of patients with expected clinical benefit from alkylating agents.